Loading...

Home
Stock
BFRG

BFRG Overview

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

BFRG Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

0.589

Open

0.540

VWAP

0.57

Vol

149.93K

Mkt Cap

6.59M

Low

0.530

Amount

84.82K

EV/EBITDA(TTM)

--

Total Shares

11.41M

EV

4.68M

EV/OCF(TTM)

--

P/S(TTM)

48.58

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

Show More

Events Timeline

(ET)

2026-02-04

07:40:00

BullFrog AI Holdings Launches New Drug Decision Engine

2026-01-27 (ET)

2026-01-27

07:40:00

BullFrog AI Releases White Paper on Data Harmonization in Life Sciences

2026-01-06 (ET)

2026-01-06

07:50:00

BullFrog AI Highlights Nearly Threefold Increase in Survival Rates in Pancreatic Cancer Trial

2025-12-30 (ET)

2025-12-30

08:30:00

BullFrog AI Releases Annual Shareholder Letter, Outlook for 2026

2025-11-18 (ET)

2025-11-18

09:58:55

Bullfrog AI Releases Whitepaper on Artificial Intelligence Applications in Bioinformatics

2025-09-30 (ET)

2025-09-30

08:24:33

Bullfrog AI reveals growth of its internal sales team

2025-09-25 (ET)

2025-09-25

08:07:54

Bullfrog AI and Sygnature Announce the Official Launch of BullFrog Networks Sales

2025-09-08 (ET)

2025-09-08

08:13:40

Bullfrog AI Shares Progress on Partnership with Eleison

2025-07-22 (ET)

2025-07-22

08:09:04

Bullfrog AI announces white paper on smarter drug development

News

Newsfilter

02-04Newsfilter

BullFrog AI Launches New Scenario-Based Decision Engine for R&D

Technology Launch: BullFrog AI is set to launch a new scenario-based decision engine on March 25, 2026, aimed at enhancing its existing bfPREP™ and bfLEAP® platforms, thereby improving the intelligence workflow in drug development.
Enhanced Decision-Making: The new engine utilizes proprietary algorithms to test portfolio decisions against multiple explicit scenarios, helping to identify options that perform well across various strategic futures, thus optimizing R&D strategies.
Addressing Market Needs: With over $200 billion spent annually by life sciences and pharmaceutical companies on R&D and a staggering 90% clinical trial failure rate, the introduction of this technology aims to improve return on investment and mitigate R&D risks.
Industry-Leading Advantage: According to BullFrog AI Founder and CEO Vin Singh, this technology is unique globally, providing more flexible strategic decision support that accelerates the drug discovery and development process.

Newsfilter

01-27Newsfilter

BullFrog AI Releases White Paper on Data Harmonization in Life Sciences

Importance of Data Harmonization: BullFrog AI's white paper emphasizes that data harmonization is a hidden prerequisite for reliable AI/ML analysis, aiming to transform complex biomedical data into actionable insights through bfPREPTM, thereby enhancing drug development success rates.
Technological Advantage: The company leverages bfPREPTM to quickly identify and standardize fragmented biomedical data, ensuring dataset reliability, allowing research teams to focus more on interpreting results and study design rather than data processing.
Challenges in AI Pipelines: The white paper highlights that modern AI pipelines often fail in life sciences due to peculiarities in data processing, and BullFrog AI proposes a practical harmonization framework built on three pillars to address these issues and improve data analysis effectiveness.
Enhancing Clinical Trial Success Rates: By utilizing bfPREPTM, BullFrog AI aims to reduce clinical trial failure rates, enabling teams to utilize data more efficiently and accelerate drug discovery and development processes, further solidifying its market position in the biopharma sector.

Newsfilter

2025-12-30Newsfilter

BullFrog AI Releases 2025 Shareholder Letter, Outlines 2026 Commercialization Goals

Technological Advancement: In 2025, BullFrog AI made significant strides in technology, transitioning from platform development to commercialization, which is expected to drive rapid commercial engagement in 2026 and enhance the company's competitiveness in the pharmaceutical industry.
Commercial Collaboration: The partnership with Sygnature Discovery is anticipated to generate significant revenue through 2028, as its global business development team actively promotes BullFrog Data Networks™ to biopharma clients, thereby expanding market reach.
Data Preparation Tool: The launch of bfPREP™ significantly reduces data preparation timelines from months to days, enhancing BullFrog AI's ability to engage earlier in the drug development process and facilitating deeper analytical collaborations.
Capital Management: BullFrog AI maintains an annual burn rate of approximately $6.2 million, and its flexible capital allocation strategy allows each significant partnership to potentially improve financial conditions substantially, supporting future growth investments.

NASDAQ.COM

2025-11-19NASDAQ.COM

Nutex Health Rises 21% in After-Hours Trading Following Revenue Increase; Biotech Competitors Also See Gains on Tuesday

Nutex Health's Performance: Nutex Health Inc. saw a significant after-hours surge of 20.97% to $120.00 following a quarterly report that revealed a net loss of $17.7 million but a remarkable 220.7% increase in revenue year-over-year to $244.0 million.
Bullfrog AI Holdings Update: Bullfrog AI Holdings, Inc. gained 5.87% to $0.9798 in after-hours trading, likely due to investor positioning ahead of its upcoming technical presentation at the AI Drug Discovery & Development Summit 2025.
Clearside Biomedical's Recovery: Clearside Biomedical, Inc. rose 6.51% to $3.27 after reporting a narrower net loss of $5.97 million, although its revenue fell sharply to $201 thousand from $1.04 million a year ago.
Aytu BioPharma and OKYO Pharma Developments: Aytu BioPharma, Inc. climbed 8.91% to $2.20 after reporting a first-quarter net income increase, while OKYO Pharma Limited edged up 2.44% to $2.18, preparing for a presentation on its investigational drug candidate for neuropathic corneal pain.

Newsfilter

2025-11-18Newsfilter

BullFrog AI Releases Whitepaper on Utilizing AI in Bioinformatics: Transforming Complex Data into Practical Insights

New Whitepaper Release: BullFrog AI Holdings has published a whitepaper titled "AI in Bioinformatics," highlighting their technology's ability to transform complex data into actionable insights for drug development.
Addressing Bioinformatics Challenges: The whitepaper identifies key pitfalls in bioinformatics that contribute to high clinical trial failure rates and presents BullFrog AI's bfLEAP platform as a solution through causal inference modeling.
Industry Transformation Potential: BullFrog AI aims to bridge the gap between data availability and actionable biological understanding, positioning its modular approach as essential for AI-enabled R&D in pharmaceuticals and biotech.
Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future performance and potential, emphasizing the uncertainties and risks involved in their projections.

SeekingAlpha

2025-10-10SeekingAlpha

Bullfrog AI seeks approval to offer 5 million shares of common stock for shareholders.

Stock Offering: Bullfrog AI (NASDAQ: BFRG) has filed to sell 5 million shares of common stock for existing holders.
Preliminary Prospectus: The filing is a preliminary prospectus and does not constitute an offer to sell the shares.

Valuation Metrics

The current forward P/E ratio for Bullfrog AI Holdings Inc (BFRG.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Bullfrog AI Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding BFRG

Trading Trends

Insider

Hedge Fund

Congress Trading

People Also Watch

Frequently Asked Questions

What is Bullfrog AI Holdings Inc (BFRG) stock price today?

The current price of BFRG is 0.5778 USD — it has decreased -0.35

What is Bullfrog AI Holdings Inc (BFRG)'s business?

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma.

What is the price predicton of BFRG Stock?

Wall Street analysts forecast BFRG stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRG is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Bullfrog AI Holdings Inc (BFRG)'s revenue for the last quarter?

Bullfrog AI Holdings Inc revenue for the last quarter amounts to 83.41K USD, decreased

What is Bullfrog AI Holdings Inc (BFRG)'s earnings per share (EPS) for the last quarter?

Bullfrog AI Holdings Inc. EPS for the last quarter amounts to -0.15 USD, decreased -31.82

How many employees does Bullfrog AI Holdings Inc (BFRG). have?

Bullfrog AI Holdings Inc (BFRG) has 9 emplpoyees as of March 03 2026.

What is Bullfrog AI Holdings Inc (BFRG) market cap?

Today BFRG has the market capitalization of 6.59M USD.